The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).
 
Katsuya Hirano
Honoraria - AstraZeneca Japan
 
Akito Hata
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Yuta Yamanaka
No Relationships to Disclose
 
Toshiyuki Sumi
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Ono Pharmaceutical
 
Motohiro Tamiya
Honoraria - Amgen; Asahi Kasei; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Pfizer
Research Funding - Boehringer Ingelheim; MSD; Ono Pharmaceutical
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Yuko Oya
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD; Novartis; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Lilly
 
Kosuke Hamai
Honoraria - Astrazeneca Pharmaceutical co.; Boehringer Ingelheim Pharmaceutical co.; Lilly
 
Nobuyuki Katakami
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Maruishi Pharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Katsuhiko Iwasaki
Employment - Healthecare Consulting Inc.
 
Tatsuhiro Uenishi
Employment - Healthecare Consulting Inc.
 
Kinya Kokubo
Employment - Healthecare Consulting Inc. (I); MSD (I)
Leadership - Healthecare Consulting Inc.
Stock and Other Ownership Interests - Healthecare Consulting Inc.; MSD (I)
Honoraria - TOPPAN Holdings Inc.
Consulting or Advisory Role - Healthecare Consulting Inc.
Speakers' Bureau - TOPPAN Holdings Inc.
Research Funding - Intage Real World Inc.
 
Ataru Igarashi
Honoraria - ABBVIE/ABBOTT; GlaxoSmithKline K.K.; Novartis; Novo Nordisk; Pfizer
Consulting or Advisory Role - argenx; Asahi Kasei; GlaxoSmithKline K.K.; Janssen; Lilly Japan; Novartis; Novo Nordisk; Ono Pharmaceutical; Pfizer; Takeda
Speakers' Bureau - Chugai Pharma; Moderna Therapeutics; MSD K.K
Research Funding - Becton Dickinson; Edwards Lifesciences; Eisai; Intuitive Japan; Janssen; Milliman; Taiho Pharmaceutical; Takeda; Varian Medical Systems